Berkshire Asset Management LLC PA Sells 29,168 Shares of Pfizer Inc. $PFE

Berkshire Asset Management LLC PA trimmed its stake in shares of Pfizer Inc. (NYSE:PFE) by 22.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 99,438 shares of the biopharmaceutical company’s stock after selling 29,168 shares during the quarter. Berkshire Asset Management LLC PA’s holdings in Pfizer were worth $2,476,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also bought and sold shares of PFE. Howe & Rusling Inc. raised its stake in shares of Pfizer by 34.3% during the fourth quarter. Howe & Rusling Inc. now owns 41,068 shares of the biopharmaceutical company’s stock valued at $1,023,000 after acquiring an additional 10,488 shares during the last quarter. Rothschild Wealth LLC grew its stake in shares of Pfizer by 147.8% in the fourth quarter. Rothschild Wealth LLC now owns 32,285 shares of the biopharmaceutical company’s stock worth $804,000 after purchasing an additional 19,254 shares during the last quarter. Aster Capital Management DIFC Ltd bought a new stake in shares of Pfizer in the fourth quarter worth about $833,000. Hollow Brook Wealth Management LLC increased its holdings in Pfizer by 24.3% during the 4th quarter. Hollow Brook Wealth Management LLC now owns 174,152 shares of the biopharmaceutical company’s stock valued at $4,336,000 after purchasing an additional 34,001 shares during the period. Finally, Rakuten Investment Management Inc. raised its position in Pfizer by 773.9% during the 4th quarter. Rakuten Investment Management Inc. now owns 747,946 shares of the biopharmaceutical company’s stock valued at $18,699,000 after purchasing an additional 662,360 shares during the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Price Performance

Shares of PFE stock opened at $26.04 on Wednesday. The business’s fifty day moving average is $26.34 and its 200 day moving average is $26.34. The company has a quick ratio of 0.94, a current ratio of 1.25 and a debt-to-equity ratio of 0.67. The stock has a market cap of $148.41 billion, a price-to-earnings ratio of 19.88 and a beta of 0.34. Pfizer Inc. has a twelve month low of $23.11 and a twelve month high of $28.75.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, beating the consensus estimate of $0.72 by $0.03. The business had revenue of $14.45 billion during the quarter, compared to analyst estimates of $13.84 billion. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The company’s revenue for the quarter was up 5.4% on a year-over-year basis. During the same quarter last year, the firm posted $0.92 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Research analysts expect that Pfizer Inc. will post 2.99 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, June 12th. Shareholders of record on Friday, May 8th were issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 6.6%. The ex-dividend date was Friday, May 8th. Pfizer’s dividend payout ratio is 131.30%.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on PFE shares. HSBC lifted their price objective on Pfizer from $29.00 to $32.00 and gave the stock a “buy” rating in a research report on Tuesday, March 17th. Weiss Ratings raised Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, May 6th. Royal Bank Of Canada upgraded shares of Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 price target on the stock in a report on Tuesday, June 9th. Argus upgraded shares of Pfizer from a “hold” rating to a “buy” rating and set a $35.00 price objective for the company in a report on Monday, March 2nd. Finally, BMO Capital Markets reaffirmed an “outperform” rating and issued a $30.00 target price on shares of Pfizer in a research report on Monday, March 9th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, twelve have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $28.82.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer’s obesity pipeline gained traction after detailed Phase 2b data for berobenatide showed proof of concept, favorable tolerability, and low reported adverse events. Pfizer has already moved the program into Phase 3, which could support longer-term growth expectations. Pfizer Obesity Pipeline Gains Traction As Berobenatide Data Support Valuation
• Positive Sentiment: CEO comments that Pfizer could return to high-single-digit growth suggest the business may be stabilizing faster than some investors expected, reinforcing the idea that the company’s recent weakness may be overdone. Here’s When Pfizer’s CEO Says the Company Might Get Back to Generating High-Single-Digit Growth
• Neutral Sentiment: Pfizer is drawing heavy investor interest and analyst coverage, with recent research pieces focusing on its discounted valuation, pipeline prospects, and post-COVID growth outlook. That keeps sentiment active, but the articles do not point to a single new catalyst. Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know
• Neutral Sentiment: Pfizer also remained in the news through broader healthcare coverage and research roundups, but these items appear informational rather than stock-moving. Top Research Reports for Pfizer, Altria & Newmont Corp.
• Negative Sentiment: Some coverage continues to frame Pfizer as a value stock facing fading COVID revenue and looming patent-cliff pressure, which reminds investors of the company’s near-term growth challenges even as pipeline efforts progress. Is Pfizer’s Discounted Valuation a Buying Opportunity or a Value Trap?

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.